Refractory Acute Myeloid Leukemia Clinical Trials

147 clinical trials for Refractory Acute Myeloid Leukemia across international registries, including 43 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia — RECRUITING · PHASE1
• Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia — RECRUITING · PHASE1
• TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts — RECRUITING · PHASE1
• A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — RECRUITING · PHASE1
• Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML — RECRUITING · PHASE1
• Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia — RECRUITING · PHASE1
• 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia — RECRUITING · PHASE1
• A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia — RECRUITING · PHASE1
• 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome — RECRUITING · PHASE1
• A Study of CRD3874-SI in People With Leukemia — RECRUITING · PHASE1
• 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — RECRUITING · PHASE2
• Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — RECRUITING · PHASE1
• Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes — RECRUITING · PHASE1
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma — RECRUITING · PHASE1
• Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia — RECRUITING · PHASE2
• Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia — RECRUITING · PHASE2
• Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse — RECRUITING · PHASE1
• SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation — RECRUITING · PHASE1
• Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms — RECRUITING · PHASE1
• Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm — RECRUITING · PHASE1
• Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML — RECRUITING · PHASE1
• Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction — RECRUITING · PHASE1
• CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) — RECRUITING · PHASE1
• Tazemetostat and Palbociclib With CPX-351for R/R AML — RECRUITING · PHASE1
• Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies — RECRUITING · PHASE1
• Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation — RECRUITING · PHASE2
• CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia — RECRUITING · PHASE1
• Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy — RECRUITING · PHASE1
• A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) — RECRUITING · PHASE1
• Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome — RECRUITING · PHASE1
• Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML — RECRUITING · PHASE2
• VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS — RECRUITING · PHASE2
• IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML — RECRUITING · PHASE3
• ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome — ACTIVE_NOT_RECRUITING · PHASE1
• Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome — COMPLETED · PHASE2
• MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia — SUSPENDED · PHASE1
• Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome — SUSPENDED · PHASE1
• Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory — SUSPENDED · PHASE1
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2

Refine this search